FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025003676> ?p ?o ?g. }

• W3025003676 endingPage "842" @default.
• W3025003676 startingPage "832" @default.
• W3025003676 abstract "Patients with advanced or metastatic oesophageal squamous cell carcinoma have poor prognosis and few treatment options after first-line therapy. We aimed to assess efficacy and safety of the anti-PD-1 antibody camrelizumab versus investigator's choice of chemotherapy in previously treated patients.ESCORT is a randomised, open-label, phase 3 study of patients aged 18 to 75 years with a histological or cytological diagnosis of advanced or metastatic oesophageal squamous cell carcinoma done at 43 hospitals in China. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had progressed on, or were intolerant to, first-line standard therapy. Patients were randomly assigned (1:1) to camrelizumab (200 mg every 2 weeks) or chemotherapy with docetaxel (75 mg/m2 every 3 weeks) or irinotecan (180 mg/m2 every 2 weeks), all given intravenously. Central randomisation was done using the Randomization and Trial Supply Management system with block size randomly generated as four or six and stratified by disease and ECOG performance status. The primary endpoint was overall survival, assessed in randomised patients who had received at least one dose of treatment. Safety was assessed in all treated patients. The trial is registered with ClinicalTrials.gov, NCT03099382, and is closed to new participants.From May 10, 2017, to July 24, 2018, 457 (75%) of 607 screened patients were randomly assigned to treatment, of whom 228 received camrelizumab treatment and 220 received chemotherapy. As of data cutoff on May 6, 2019, with a median follow-up time of 8·3 months (IQR 4·1-12·8) in the camrelizumab group and 6·2 months (3·6-10·1) in the chemotherapy group, median overall survival was 8·3 months (95% CI 6·8-9·7) in the camrelizumab group and 6·2 months (5·7-6·9) in the chemotherapy group (hazard ratio 0·71 [95% CI 0·57-0·87]; two-sided p=0·0010). The most common treatment-related adverse events of grade 3 or worse were anaemia (camrelizumab vs chemotherapy: six [3%] vs 11 [5%]), abnormal hepatic function (four [2%] vs one [<1%]), and diarrhoea (three [1%] vs nine [4%]). Serious treatment-related adverse events occurred in 37 (16%) of 228 patients in the camrelizumab group, and in 32 (15%) of 220 patients in the chemotherapy group. Ten treatment-related deaths occurred, seven (3%) in the camrelizumab group (three deaths from unknown causes, one enterocolitis, one hepatic function abnormal, one pneumonitis, and one myocarditis) and three (1%) in the chemotherapy group (two deaths from unknown causes, and one gastrointestinal haemorrhage).Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy, with a manageable safety profile. It might represent a potential option of standard second-line treatment for patients with oesophageal squamous cell carcinoma in China.Jiangsu Hengrui Medicine." @default.
• W3025003676 created "2020-05-21" @default.
• W3025003676 creator A5002727383 @default.
• W3025003676 creator A5002816521 @default.
• W3025003676 creator A5003077724 @default.
• W3025003676 creator A5004295637 @default.
• W3025003676 creator A5010738468 @default.
• W3025003676 creator A5012208123 @default.
• W3025003676 creator A5013718591 @default.
• W3025003676 creator A5019233394 @default.
• W3025003676 creator A5019360674 @default.
• W3025003676 creator A5022938518 @default.
• W3025003676 creator A5023128001 @default.
• W3025003676 creator A5023468924 @default.
• W3025003676 creator A5025014785 @default.
• W3025003676 creator A5029848730 @default.
• W3025003676 creator A5032988856 @default.
• W3025003676 creator A5034205421 @default.
• W3025003676 creator A5035701638 @default.
• W3025003676 creator A5037658093 @default.
• W3025003676 creator A5037920295 @default.
• W3025003676 creator A5042174429 @default.
• W3025003676 creator A5042241049 @default.
• W3025003676 creator A5042560788 @default.
• W3025003676 creator A5044447392 @default.
• W3025003676 creator A5049678335 @default.
• W3025003676 creator A5052590910 @default.
• W3025003676 creator A5053266269 @default.
• W3025003676 creator A5053506947 @default.
• W3025003676 creator A5059392900 @default.
• W3025003676 creator A5060002817 @default.
• W3025003676 creator A5061130250 @default.
• W3025003676 creator A5061402622 @default.
• W3025003676 creator A5062179244 @default.
• W3025003676 creator A5064422431 @default.
• W3025003676 creator A5066716873 @default.
• W3025003676 creator A5067814400 @default.
• W3025003676 creator A5068301710 @default.
• W3025003676 creator A5069498085 @default.
• W3025003676 creator A5070745750 @default.
• W3025003676 creator A5073651132 @default.
• W3025003676 creator A5075221223 @default.
• W3025003676 creator A5076731937 @default.
• W3025003676 creator A5078989023 @default.
• W3025003676 creator A5079451346 @default.
• W3025003676 creator A5081604639 @default.
• W3025003676 creator A5085215477 @default.
• W3025003676 creator A5087661837 @default.
• W3025003676 creator A5089282308 @default.
• W3025003676 date "2020-06-01" @default.
• W3025003676 modified "2023-10-17" @default.
• W3025003676 title "Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study" @default.
• W3025003676 cites W1567205022 @default.
• W3025003676 cites W1970194999 @default.
• W3025003676 cites W1975239262 @default.
• W3025003676 cites W2046284161 @default.
• W3025003676 cites W2063209855 @default.
• W3025003676 cites W2078481325 @default.
• W3025003676 cites W2099526120 @default.
• W3025003676 cites W2128563985 @default.
• W3025003676 cites W2138098788 @default.
• W3025003676 cites W2330814896 @default.
• W3025003676 cites W2596604644 @default.
• W3025003676 cites W2789258259 @default.
• W3025003676 cites W2884883038 @default.
• W3025003676 cites W2889646458 @default.
• W3025003676 cites W2890100090 @default.
• W3025003676 cites W2897612290 @default.
• W3025003676 cites W2898244744 @default.
• W3025003676 cites W2903527992 @default.
• W3025003676 cites W2912167213 @default.
• W3025003676 cites W2923967990 @default.
• W3025003676 cites W2943432615 @default.
• W3025003676 cites W2976652879 @default.
• W3025003676 doi "https://doi.org/10.1016/s1470-2045(20)30110-8" @default.
• W3025003676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32416073" @default.
• W3025003676 hasPublicationYear "2020" @default.
• W3025003676 type Work @default.
• W3025003676 sameAs 3025003676 @default.
• W3025003676 citedByCount "304" @default.
• W3025003676 countsByYear W30250036762020 @default.
• W3025003676 countsByYear W30250036762021 @default.
• W3025003676 countsByYear W30250036762022 @default.
• W3025003676 countsByYear W30250036762023 @default.
• W3025003676 crossrefType "journal-article" @default.
• W3025003676 hasAuthorship W3025003676A5002727383 @default.
• W3025003676 hasAuthorship W3025003676A5002816521 @default.
• W3025003676 hasAuthorship W3025003676A5003077724 @default.
• W3025003676 hasAuthorship W3025003676A5004295637 @default.
• W3025003676 hasAuthorship W3025003676A5010738468 @default.
• W3025003676 hasAuthorship W3025003676A5012208123 @default.
• W3025003676 hasAuthorship W3025003676A5013718591 @default.
• W3025003676 hasAuthorship W3025003676A5019233394 @default.
• W3025003676 hasAuthorship W3025003676A5019360674 @default.
• W3025003676 hasAuthorship W3025003676A5022938518 @default.
• W3025003676 hasAuthorship W3025003676A5023128001 @default.
• W3025003676 hasAuthorship W3025003676A5023468924 @default.
• W3025003676 hasAuthorship W3025003676A5025014785 @default.

• next